Key result
Experimental heart failure increases plasma adrenomedullin by ~160% compared to controls.
Why the study?
Adrenomedullin plays an important role in cardiorenal regulation, but its plasma, urinary, cardiac, and renal tissue concentrations and localizations in experimental congestive heart failure were not established.
Answers are grounded in this paper and cite their sources.
Adrenomedullin elevation in experimental HF is hypothesis-generating; human studies required before biomarker or therapeutic implications.
Adrenomedullin (ADM) is a new member of a family of vasodilating and natriuretic peptides that plays an important role in cardiorenal regulation. This study was designed to establish the plasma, urinary, cardiac, and renal tissue concentrations and immunohistochemical localizations of ADM in normal dogs and dogs with experimental congestive heart failure (CHF) produced by rapid ventricular pacing. Plasma ADM concentration was 5.6 +/- 0.4 pg/ml in normal dogs and significantly increased to 14.5 +/- 2.5 pg/ml in CHF dogs (P < 0.05). Ventricular and renal tissue ADM were significantly increased in CHF dogs compared with normals. Immunohistochemical examination revealed positive ADM immunostaining within the myocytes, and ventricular ADM immunoreactivity was significantly more intense in CHF dogs than in normals. ADM immunoreactivity was also observed in the glomerulus, distal tubules, and medullary collecting duct cells in the kidney, and the intensities of ADM immunoreactivity in these sites were increased in CHF dogs compared with normals. In addition, ventricular ADM was a powerful marker for left ventricular mass, and circulating ADM correlated positively with left ventricular end-diastolic pressure and inversely with cardiac output and ejection fraction. Despite an increase in renal tissue ADM, urinary ADM did not increase in CHF dogs. The current study demonstrates that plasma concentration of ADM is increased in experimental CHF and that ventricular and renal ADM is activated in the progression of CHF. Tissue and circulating ADM also are markers for the alterations in myocardial structure and function. This study supports a potential role for ADM in the neurohumoral activation in experimental CHF.
No takes yet. Share an insight, caveat, or question.
Jougasaki et al. (1997) studied Congestive heart failure. Rapid ventricular pacing (experimental CHF) vs. Normal dogs was evaluated on Plasma adrenomedullin (ADM) concentration (p=<0.05). Experimental congestive heart failure significantly increased plasma adrenomedullin concentrations to 14.5 pg/ml compared to 5.6 pg/ml in normal dogs.
Synapse has enriched 10 related papers. Consider them for comparative context: